Intellectual PROPERTY rights

Isofol has an active strategy to protect the company’s intellectual property rights and to ensure that these cover the markets that are important to the company. The patent portfolio covers both the formulation technology, dosage regime and use. Protecting company and trade secrets has been an important strategic area for the company in order to ensure the company’s commercial freedom of action.

The company’s intellectual property rights are protected primarily through patents and patent applications. Isofol works continuously and proactively to protect the intellectual property rights of arfolitixorin. The patent portfolio consists of several types of patents; substance, formulation and how they should be used in treatment.

Arfolitixorin currently has granted patent protection in the USA, Europe, Japan, Canada, Australia and South Korea, for use in most major cancers, until the year 2038. The substance itself, arfolitixorin as a salt, has granted patents until the year 2037 in the USA and until the year 2034 in the rest of the world (for example in Europe and China). In 2022, a European patent was granted covering the clinical use of a biomarker assay to detect cancer patients’ ability to respond to folate-based cancer treatments.

Isofol has an external patent expert who manages contact and relations with the important collaboration partners who work with the company’s patent portfolio.

Last updated 05-14-2024

Scroll to Top